The utility of a model-based cost-effectiveness analysis of degarelix versus leuprolide in the therapy of hormone-dependent advanced prostate cancer. (2013). Farmeconomia. Health Economics and Therapeutic Pathways, 14(3), 131-146. https://doi.org/10.7175/fe.v14i3.700